<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Friends of Heroes - National Light The Night Team &#187; TAP</title>
	<atom:link href="http://www.friendsofheroes.org/tag/tap/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.friendsofheroes.org</link>
	<description></description>
	<lastBuildDate>Mon, 06 Sep 2010 04:06:00 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=abc</generator>
		<item>
		<title>Therapy Acceleration Program (TAP)</title>
		<link>http://www.friendsofheroes.org/2008/07/therapy-acceleration-program-tap/</link>
		<comments>http://www.friendsofheroes.org/2008/07/therapy-acceleration-program-tap/#comments</comments>
		<pubDate>Mon, 28 Jul 2008 18:32:14 +0000</pubDate>
		<dc:creator>Christy</dc:creator>
				<category><![CDATA[Cancer Research Notes]]></category>
		<category><![CDATA[Leukemia & Lymphoma Society]]></category>
		<category><![CDATA[TAP]]></category>
		<category><![CDATA[Therapy Acceleration Program]]></category>

		<guid isPermaLink="false">http://www.friendsofheroes.org/?p=163</guid>
		<description><![CDATA[TAP on a Roll LLS&#8217;s innovative new partnership program, the Therapy Acceleration Program (TAP), continues to grow and help create opportunities for new blood cancer treatments. Founded in 2007, TAP supports private sector and academic-based projects with the goal of moving more blood cancer therapies into the development pipeline. The program now has nine partnerships]]></description>
			<content:encoded><![CDATA[<p class="dropcap-first">
<table class="MsoNormalTable" style="width: 519px; height: 459px; mso-cellspacing: 0in; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" border="0" cellspacing="0" cellpadding="0" width="519">
<tbody>
<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;">
<td style="background-color: transparent; border: #f0f0f0; padding: 0in;" valign="top"><strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">TAP on a Roll</span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0pt;">
<div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">LLS&#8217;s innovative new partnership program, the <em>Therapy Acceleration Program (TAP)</em>, continues to grow and help create opportunities for new blood cancer treatments.</span></div>
<div><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Founded in 2007, <em>TAP </em>supports private sector and academic-based projects with the goal of moving more blood cancer therapies into the development pipeline.<br />
The program now has nine partnerships with a range of companies, universities and hospitals.</span></div>
<div><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&#8220;We&#8217;re definitely progressing,&#8221; said Louis DeGennaro, Ph.D., LLS&#8217;s chief scientific officer. &#8220;These partnerships represent the beginning of a fruitful, long-term collaboration with some of the world&#8217;s leading innovators.&#8221;</span></div>
<div><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;"><em>TAP</em> partnerships include:</span><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;"> </p>
<p></span></div>
<ul type="disc">
<li class="MsoNormal" style="margin: 0in 0in 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">Anjin Group</span></strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">, a biotechnology company with offices in Maryland and Massachusetts. <em>TAP</em> is funding the company&#8217;s lead product, a novel therapy for acute myelogenous leukemia.</span><span style="mso-fareast-font-family: 'Times New Roman';"><span style="font-size: small;"><span style="font-family: Times New Roman;"> </span></span></span></li>
<li class="MsoNormal" style="margin: 0in 0in 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">Cleveland Clinic</span></strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">. LLS and the world-renowned Cleveland Clinic are joining forces to provide potentially lifesaving clinical trials for blood cancer patients.</span><span style="mso-fareast-font-family: 'Times New Roman';"><span style="font-size: small;"><span style="font-family: Times New Roman;"> </span></span></span></li>
<li class="MsoNormal" style="margin: 0in 0in 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">MannKind Corp</span></strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">., a biotechnology company in California. <em>TAP</em> is supporting the company in its efforts to develop drugs to treat T-cell-based leukemia and lymphoma.</span><span style="mso-fareast-font-family: 'Times New Roman';"><span style="font-size: small;"><span style="font-family: Times New Roman;"> </span></span></span></li>
<li class="MsoNormal" style="margin: 0in 0in 0pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">Memgen LLC</span></strong><span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman';">, a San Diego-based biotechnology company. <em>TAP</em> is supporting a clinical trial to test a novel therapy for a form of chronic lymphocytic leukemia.</span></li>
</ul>
<p><span style="font-size: 10pt;"><span style="color: #cc0000;"><br />
</span>Taken form The LLS newsline. For more info please visit. <span style="font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><a href="www.lls.org"><span style="font-size: 7.5pt;"><span style="color: #0000ff;">www.LLS.org</span></span></a> </span></span></td>
</tr>
</tbody>
</table>
<div class='wpfblike' style='height: 40px;'><fb:like href='http://www.friendsofheroes.org/2008/07/therapy-acceleration-program-tap/' layout='default' show_faces='false' width='400' action='like' colorscheme='light' /></div>
]]></content:encoded>
			<wfw:commentRss>http://www.friendsofheroes.org/2008/07/therapy-acceleration-program-tap/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
